StreetInsider.com News Articles

Nuvation Bio to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences:

Nuvation Bio to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

Form 4 Nuvation Bio Inc. For: Aug 19 Filed by: Hattersley Gary

Fri, 21 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260821/26962072.html

Form 4 Nuvation Bio Inc. For: Aug 19 Filed by: Hattersley Gary

Fri, 21 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260821/26962072.html

Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight

Fri, 21 Aug 2026 06:05:35 -0400

(Updated - August 21, 2026 6:05 AM EDT)

Cantor Fitzgerald analyst Li Watsek initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Overweight rating.

The analyst comments "We initiate coverage of Nuvation Bio (NUVB) at Overweight. Nuvation is a low-risk, high-reward commercial-stage oncology story built on two best-in-class targeted therapies. We believe the Street materially undervalues the size of both markets, driven in part by multi-year treatment duration. Ibtrozi (taletrectinib), a next-generation ROS1 inhibitor launched in 2025, provides the valuation floor. We believe growing 1L use in ROS1+ NSCLC (non-small cell lung cancer) and a multi-year duration of therapy should drive

Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight

Fri, 21 Aug 2026 06:05:35 -0400

(Updated - August 21, 2026 6:05 AM EDT)

Cantor Fitzgerald analyst Li Watsek initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Overweight rating.

FDA grants Nuvation Bio fast track status for brain cancer drug

Thu, 20 Aug 2026 08:00:31 -0400

Nuvation Bio Inc. (NYSE: NUVB) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to safusidenib, the company's investigational oral drug candidate for the treatment of IDH1-mutant glioma.

The designation, granted in August 2026, is intended to facilitate development and expedite the review of drugs that treat serious conditions with unmet medical need. It allows for more frequent FDA interactions during development and, if relevant criteria are met, may permit rolling review of a marketing application.

The FDA's decision was based on clinical data from Nuvation Bio's safusidenib program. In the Phase 2 J201 study, at a median

FDA grants Nuvation Bio fast track status for brain cancer drug

Thu, 20 Aug 2026 08:00:31 -0400

The FDA's decision was based on clinical data from Nuvation Bio's safusidenib program. In the Phase 2 J201 study, at a median

FDA grants Nuvation Bio fast track status for brain cancer drug

Thu, 20 Aug 2026 08:00:31 -0400

The FDA's decision was based on clinical data from Nuvation Bio's safusidenib program. In the Phase 2 J201 study, at a median

FDA grants Nuvation Bio fast track status for brain cancer drug

Thu, 20 Aug 2026 08:00:31 -0400

The FDA's decision was based on clinical data from Nuvation Bio's safusidenib program. In the Phase 2 J201 study, at a median

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

Thu, 20 Aug 2026 08:00:00 -0400

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma